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ABSTRACT
Introduction Myocardial protection against ischaemic- 
reperfusion injury is a key determinant of heart function 
and outcome following cardiac surgery in children. 
However, with current strategies, myocardial injury occurs 
routinely following aortic cross- clamping, as demonstrated 
by the ubiquitous rise in circulating troponin. Remote 
ischaemic preconditioning, the application of brief, non- 
lethal cycles of ischaemia and reperfusion to a distant 
organ or tissue, is a simple, low- risk and readily available 
technique which may improve myocardial protection. 
The Bilateral Remote Ischaemic Conditioning in Children 
(BRICC) trial will assess whether remote ischaemic 
preconditioning, applied to both lower limbs immediately 
prior to surgery, reduces myocardial injury in cyanotic and 
acyanotic young children.
Methods and analysis The BRICC trial is a two- centre, 
double- blind, randomised controlled trial recruiting up to 
120 young children (age 3 months to 3 years) undergoing 
primary repair of tetralogy of Fallot or surgical closure 
of an isolated ventricular septal defect. Participants will 
be randomised in a 1:1 ratio to either bilateral remote 
ischaemic preconditioning (3×5 min cycles) or sham 
immediately prior to surgery, with follow- up until discharge 
from hospital or 30 days, whichever is sooner. The primary 
outcome is reduction in area under the time- concentration 
curve for high- sensitivity (hs) troponin- T release in the 
first 24 hours after aortic cross- clamp release. Secondary 
outcome measures include peak hs- troponin- T, vasoactive 
inotrope score, arterial lactate and central venous oxygen 
saturations in the first 12 hours, and lengths of stay in the 
paediatric intensive care unit and the hospital.
Ethics and dissemination The trial was approved by the 
West Midlands- Solihull National Health Service Research 
Ethics Committee (16/WM/0309) on 5 August 2016. 
Findings will be disseminated to the academic community 
through peer- reviewed publications and presentation 
at national and international meetings. Parents will be 
informed of the results through a newsletter in conjunction 
with a local charity.
Trial registration number ISRCTN12923441.
INTRODUCTION
Myocardial protection
During most surgery for congenital heart 
disease, it is necessary to stop the heart, 
allowing access to a still and bloodless field to 
enable repair of intracardiac defects. Cardio-
plegia and hypothermia have been funda-
mental to arresting the heart and protecting 
against ischaemia- reperfusion (IR) injury 
during surgery for over 40 years and are 
used in approximately 3500 cardiac surgical 
operations in children in the UK and Ireland 
each year.1 However, the developing myocar-
dium exhibits marked differences in metab-
olism from the adult heart2 and as current 
techniques for cardioprotection were devel-
oped in adults, they may not be optimal for 
Strengths and limitations of this study
 ► This is the first randomised controlled trial to eval-
uate the efficacy of bilateral remote ischaemic pre-
conditioning, applied simultaneously to both lower 
limbs to provide a more intense stimulus in young 
patients undergoing surgery.
 ► It is also the first multicentre cardiac surgical trial in 
children in the UK.
 ► We will exclude neonates, in whom precondition-
ing may be harmful, and avoid the use of propofol 
anaesthesia, which is thought to interfere with the 
preconditioning pathway.
 ► A potential limitation is if exposure to cyanosis in 
those with tetralogy of Fallot has already had a pre-
conditioning effect, this could attenuate the effect of 
the intervention.
 ► The effect of the intervention may also be concealed 
if right ventricular incision, muscle resection or 
outflow tract stent removal significantly increases 
troponin release in patients with tetralogy of Fallot 
above that associated with ischaemia reperfusion.
by copyright.
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young children.3 4 Myocardial injury still occurs routinely 
following aortic cross- clamping in children,2 5 with IR 
leading to a degree of contractile impairment which may 
manifest as low cardiac output and require inotropic 
support in the early postoperative period. This is a major 
cause of morbidity and death in the early postoperative 
period6 7 and children with preoperative cyanosis are 
more vulnerable to the effects of IR than acyanotic chil-
dren.8 9 Postoperative elevation of circulating troponin is 
a biomarker of myocardial injury and has been shown to 
strongly correlate with clinical outcomes including level 
of inotropic support, duration of ventilation, ventricular 
dysfunction and early death5 10 ; consequently, it is the 
most common primary outcome measure in clinical trials 
of cardioprotection in children.11 Myocardial protection 
therefore is a key determinant of heart function and 
outcome following cardiac surgery.
Remote ischaemic preconditioning
Remote ischaemic preconditioning (RIPC) involves the 
application of brief, non- lethal cycles of ischaemia and 
reperfusion to a distant organ or tissue, such as a limb, 
to induce protection against subsequent myocardial IR 
injury.12 There are thought to be two phases of cardi-
oprotection: a first window with an immediate effect 
lasting several hours, and a second window which appears 
around 12–24 hours and lasts for 48–72 hours.13 The 
stimulus has traditionally been applied to the upper arm 
(adults) or thigh (children) using a blood pressure cuff 
inflated to above systolic pressure.14 The promise of this 
simple, low- risk, inexpensive and readily available tech-
nique as an adjunct to current methods for myocardial 
protection has prompted numerous trials in adults15–20 
and children21–28 but with mixed results. A meta- analysis 
suggested that RIPC reduces myocardial injury in both 
adult and paediatric cardiac surgery,29 but subsequently 
two large multicentre trials in adults failed to show benefit 
in either composite cardiovascular endpoints or troponin 
release19 20 ; both have been criticised for using propofol 
anaesthesia after it had been suggested to interfere with 
the preconditioning pathway.30 31
Cheung et al first demonstrated reductions in troponin 
release and perioperative inotropic requirements in a 
heterogeneous cohort of children, most of whom had 
either tetralogy of Fallot or ventricular septal defect 
(VSD).21 Several studies have found improved myocar-
dial protection in infants and young children undergoing 
tetralogy of Fallot repair28 or VSD closure,22 23 while 
others have found no benefit24 25 and suggested that 
preoperative cyanosis may have already up- regulated pro- 
survival pathways.25 The only trial in cyanosed neonates 
found no benefit, citing young age, myocardial imma-
turity and chronic hypoxaemia as potential conflicting 
factors26 ; animal models have also suggested that precon-
ditioning may have no effect32 or even be harmful33 to 
the immature myocardium. To date, no clinical trials have 
compared the effects of RIPC in patients with or without 
chronic cyanosis and its impact on preconditioning 
remains uncertain.34
In the largest paediatric trial to date, McCrindle et 
al found no benefit in clinical outcomes, physiolog-
ical markers or subgroup analyses in a mixed cohort of 
299 children27 and proposed that better than expected 
outcomes in the control group, heterogeneity of under-
lying conditions and use of propofol may have affected 
their findings. Failure to elicit a stimulus may also have 
been a key factor; manual inflation of the cuff to just 
15 mm Hg above systolic pressure may have led to periods 
of subclinical reperfusion and abolition of any precon-
ditioning response. A recent meta- analysis in children 
determined that RIPC has a cardioprotective effect, 
with reduced troponin release, lower inotrope scores 
and reduced paediatric intensive care unit (PICU) stay 
following surgery35 but was unable to include the largest 
trial in most analyses due to a lack of suitable published 
data.
Rationale
In this trial, we will test whether in young children under-
going primary repair of tetralogy of Fallot or closure of 
an isolated VSD, the two most common congenital heart 
defects requiring surgery,1 adequately delivered RIPC, 
compared with sham inflation–deflation cycles, improves 
myocardial protection. The design will enable evaluation 
of the effects of RIPC in children with and without preop-
erative cyanosis34 ; most patients with tetralogy of Fallot 
have chronic hypoxaemia while those with a VSD are not 
usually cyanotic and both groups undergo surgery at a 
similar age. We will use a more intensive two- cuff tech-
nique,18 applying a concurrent stimulus to both lower 
limbs to compensate for the lower skeletal muscle mass in 
young children. We will address methodological concerns 
by using a pressure- controlled tourniquet system set 
to at least 50 mm Hg above systolic pressure,27 avoiding 
propofol anaesthesia,30 31 and not enrolling neonates or 
other infants less than 3 months old.26 We will only seek to 
exploit the first window of preconditioning, performing 
the intervention under general anaesthesia prior to ster-
notomy, as the second window would require RIPC at least 
12 hours prior to surgery13 which may be logistically chal-
lenging, distressing to the child and their parents, and 
lead to incomplete intervention or withdrawal. Finally, 
this trial will be the first multicentre cardiac surgical trial 
in children in the UK36 and act as a primer for the devel-
opment of a network for the design and conduct of multi-




The Bilateral Remote Ischaemic Conditioning in Chil-
dren (BRICC) trial is a two- centre, double- blind, parallel 
arm, randomised controlled trial (RCT) to investigate the 
effects of RIPC and the impact of cyanosis on myocardial 
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protection in young children undergoing elective cardiac 
surgery. It will be conducted through the Birmingham 
Clinical Trials Unit (BCTU), a UK Clinical Research 
Collaboration- registered clinical trials unit with expertise 
in surgical and paediatric trials.
Inclusion and exclusion criteria
Inclusion criteria
All infants and young children, aged 3 months to 3 years 
at the time of surgery, undergoing either primary repair 
of tetralogy of Fallot or surgical closure of a VSD, with or 
without concomitant atrial septal defect (ASD) closure or 
pulmonary artery repair/augmentation, at Birmingham 
Children’s Hospital or Leeds Children’s Hospital will be 
included. Only patients with the most common form of 
tetralogy of Fallot will be included; variants such as absent 
pulmonary valve syndrome, pulmonary atresia with major 
aortopulmonary collateral arteries or with an atrioventric-
ular septal defect will not be included.
Exclusion criteria
The following children will be excluded from the study:
 ► Those requiring an additional procedure (other than 
ASD closure or pulmonary artery repair/augmenta-
tion) at the time of primary repair for example, mitral 
repair, aortic arch repair.
 ► Those with significant airway or parenchymal lung 
disease, bleeding disorder or a recent ischaemic event.
 ► Those who have undergone a previous cardiac surgical 
procedure with cardioplegic arrest.
 ► Those presenting in a critical condition and requiring 
emergency surgery.
 ► Those for whom the parents are unwilling or unable 
to give informed consent.
Recruitment
Both tetralogy of Fallot and VSD are congenital heart 
defects that usually present with gradual onset of symp-
toms such as failure to thrive, difficulty feeding, dyspnoea 
or cyanosis. The referral pathway is therefore predictable 
with most children undergoing elective surgery following 
a period of medical therapy to allow them to grow; some 
children may require a palliative procedure prior to 
repair, notably right ventricular outflow tract (RVOT) 
stenting for cyanosis in tetralogy of Fallot37 or pulmonary 
artery banding to reduce pulmonary overcirculation with 
an unrestrictive VSD. All eligible patients will be identified 
from the multidisciplinary team meeting, surgical clinics 
or waiting lists by the principal investigators at each site, 
and their parents approached to ascertain interest in the 
trial. They will be provided with a parent/guardian infor-
mation sheet (online supplemental appendix A and B) 
either in the clinic/ward or sent in the post and given at 
least 24 hours to consider their child’s participation and 
ask questions. Written informed consent will be obtained 
by a consultant surgeon prior to enrolment (online 
supplemental files C and D). The participant pathway 
through the trial is shown in figure 1.
Randomisation and blinding
On the day of surgery, participants will be randomised 
in a 1:1 ratio to either RIPC or sham procedure using a 
secure online randomisation system, with a minimisation 
algorithm incorporating the following factors:
 ► Congenital heart defect: tetralogy of Fallot or VSD.
 ► Presence of an RVOT stent in patients with tetralogy 
of Fallot.
 ► Surgical centre: Birmingham or Leeds.
To avoid any possibility of the allocation becoming 
predictable, a random element will be included in the 
algorithm. If online randomisation is unavailable, a tele-
phone helpline with emergency paper randomisation will 
be used. An independent healthcare professional, trained 
and competent in delivering the trial intervention, will 
perform the randomisation and administer the allocated 
treatment according to a standard operating procedure; 
the research nurse, surgical, anaesthetic, perfusion and 
PICU teams involved in the child’s care will remain 
blinded to group allocation throughout the trial.
Treatment arms
Intervention arm
After induction of anaesthesia but prior to sternotomy, 
the treatment group will receive RIPC induced by three 
cycles of 5- minute ischaemia and 5- minute reperfu-
sion.38 Ischaemia will be induced simultaneously in both 
lower limbs using the PTSii system (Delfi Medical Inno-
vations, Vancouver, Canada), a state- of- the- art digital 
tourniquet with precise control of occlusion pressure. 
Age- appropriate PediFit cuffs, with contour limb protec-
tion sleeves, will be placed around both thighs and 
inflated to at least 50 mm Hg above systolic pressure 
Figure 1 Participant pathway from screening to end of 
follow- up. PIS, parent information sheet; RA, right atrium; 
RIPC, remote ischaemic preconditioning; RV, right ventricle.
by copyright.
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measured in real- time via the arterial line during the isch-
aemia phase of each cycle. If one lower limb is unavail-
able, for example, required for vascular access during the 
intervention period, one cuff may be placed on the upper 
arm instead. In addition, a dummy limb will be placed 
between the patient’s legs to maintain blinding (see the 
Control arm section). Continual loss of arterial flow will 
be confirmed by distal pulse oximetry during each limb 
occlusion cycle, visible only to the person applying the 
intervention25 ; if the distal trace is not rapidly lost, the 
cuff will be tightened or the inflation pressure increased 
to achieve arterial occlusion. If pulse oximetry is not 
available, a clinical assessment will be made to deter-
mine whether there is loss of arterial flow (decreased 
lower limb temperature to touch, marked prolongation 
of capillary refill time) and reperfusion (increased lower 
limb temperature±blushing) during each cycle. Once the 
intervention has begun, each cuff must be kept on the 
same limb to ensure repeated doses of IR to the same 
muscle mass. Blinding will be maintained by covering the 
child with a surgical drape from above the nipples down-
wards including all four limbs throughout the period of 
cuff application, intervention and removal.
Control arm
Contour limb protection sleeves will be placed around 
both thighs but the PediFit cuffs will be attached to the 
dummy limb (43×300 mm polyethylene tubing) placed 
between the patient’s legs. Three sham inflation- deflation 
cycles will be performed using the PTSii system. Pulse 
oximetry monitoring will be reviewed by the person 
applying the intervention only, but no loss of trace will 
be observed during the cycles. As above, the child will 
be covered with a surgical drape to maintain blinding 
before, during and after the sham intervention.
Adherence to treatment will be defined as receiving the 
allocated treatment, and in the intervention arm, with 
loss of arterial flow (pulse oximetry or clinical assessment, 
if required) during each period of limb ischaemia.
Common aspects of care
Anaesthesia
Anaesthesia will be conducted at the discretion of the 
consultant anaesthetist and involve a balanced technique 
using volatile and intravenous anaesthesia and adjuncts, 
opioid pain relief and muscle relaxants, within the limits 
of the protocol. Propofol will not be used for induction 
or maintenance of anaesthesia; isoflurane will be the 
preferred volatile anaesthetic agent and end- tidal partial 
pressure will be recorded at the end of RIPC administra-
tion. Phenylepherine will be used for vasoconstriction, 
as required. Routine monitoring will include contin-
uous invasive arterial and central venous pressures, other 
cardiac output variables, urine output, blood gas analysis 
and near- patient clotting profile.39 Systemic anticoagula-
tion will be achieved with heparin prior to institution of 
cardiopulmonary bypass (CPB) and reversed with prota-
mine after the termination of CPB.
Surgery and perfusion
Repair of the congenital heart defect(s) will be performed 
following best clinical practice. After transfer to the oper-
ating room, the surgical checklist will be completed, 
the patient prepped and draped, and the chest opened 
through a median sternotomy. Standardised CPB will be 
established between the vena cavae and the ascending 
aorta with moderate hypothermia. An aortic cross- clamp 
will be applied to the proximal ascending aorta with inter-
mittent antegrade cold cardioplegia given via the aortic 
root for myocardial protection; patients undergoing VSD 
closure will usually receive a single dose, while those with 
tetralogy of Fallot will typically require an additional 
dose. Removal of the aortic cross- clamp with myocar-
dial reperfusion will be considered as time zero for the 
recording of postoperative events. Following completion 
of the repair and rewarming, CPB will be weaned and 
discontinued. In the event of difficulty separating from 
bypass or marked haemodynamic instability, subjective 
and objective measures of ventricular function will be 
obtained, and inotropic support instituted at the discre-
tion of the blinded operating team. Once haemodynamic 
stability and haemostasis have been achieved, the chest 
will be closed at the discretion of the surgical team and 
the patient transferred to the PICU. Standard postoper-
ative care will proceed with anticipated removal of the 
arterial line at 12 hours following surgery, removal of the 
central line at 24 hours and transfer to the ward once 
routine PICU discharge criteria have been met. All deci-
sions regarding escalation of therapy will be made by the 
blinded clinical team responsible for the care of the child 
without influence from the researchers.
Trial investigations
The schedule for the intervention and collection of 
outcome data, blood and tissue samples is shown in 
table 1.
Data collection
Clinical data will be collected by the research nurse 
before, during and after surgery. Inotrope usage in the 
first 12 hours will be used to generate a vasoactive inotrope 
score (µg/kg/min).40 41 Arterial lactate and central venous 
oxygen saturations will be recorded prior to surgery and 
at 3, 6, 9 and 12 hours. Length of stay in PICU (hours) 
and hospital (days) following surgery will be documented. 
Preoperative haematocrit and resting oxygen saturations 
in air will be used as markers of the degree of exposure 
to cyanosis. In Birmingham only, cardiac output will be 
measured over the first 12 hours following reperfusion 
using ICON (Osypka Medical, Berlin, Germany), a non- 
invasive technique for electrical velocimetry which has 
been validated in young children.42–44
Blood samples
Blood will be drawn from indwelling arterial or central 
venous lines at baseline (after induction of anaesthesia 
but prior to sternotomy) and at 3, 6, 12 and 24 hours 
by copyright.
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after reperfusion. Plasma samples for high- sensitivity (hs) 
troponin- T (Elecsys Tn- T HS, Roche, Basel, Switzerland) 
will be collected in paediatric lithium heparin tubes, 
centrifuged, split into two aliquots and stored at −80°C 
in remotely monitored freezers at each site until transfer 
for analysis at one of two core labs (Sandwell General 
Hospital, Birmingham or Russells Hall Hospital, Dudley, 
UK). Samples will be analysed in batches approximately 
every 8 months so that data on the primary outcome will 
be available to the Data Monitoring Committee prior to 
each meeting.
Tissue samples
In Birmingham only, myocardial biopsies will be obtained 
for a metabolic substudy. Right atrial samples will be 
taken soon after aortic cross- clamping (onset ischaemia) 
and just before its release (late ischaemia) to assess meta-
bolic changes in the myocardium during the period of 
ischaemia. In a subset of patients with tetralogy of Fallot, 
several samples of hypertrophic septoparietal trabeculae 
of the right ventricular infundibulum will be obtained 
at various points during ischaemia, whenever routinely 
resected. Specimens will be briefly washed in saline, 
promptly snap- frozen in liquid nitrogen and stored at 
−80°C until transfer to the Phenome Centre Birmingham 
for metabolic phenotyping. Analysis of these samples is 
exploratory and will follow a separate analytical plan (see 
the Substudies section).
Outcome measures and follow-up
Primary outcome:
Reduction in area under the time- concentration curve 
(AUC) for hs- troponin- T release in the first 24 hours after 
aortic cross- clamp release (reperfusion) as a marker of 
myocardial injury.
Secondary outcomes
 ► Peak hs- troponin- T in the first 12 hours.
 ► Total vasoactive inotrope score in the first 12 hours.
 ► Arterial lactate and central venous oxygen saturations 
in the first 12 hours.
 ► Length of postoperative stay in the PICU.
 ► Length of postoperative stay in the hospital.
Exploratory outcome
Cardiac index in the first 12 hours measured using ICON 
(Birmingham only).
Follow-up




It is hypothesised that RIPC will reduce the AUC for 
hs- troponin- T release in the first 24 hours compared 
with controls, but that exposure to hypoxaemia may 
impact on this reduction. The sample size proposed 
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postoperative troponin release, assuming a mean release 
of 350 µg/L/hour in the control group compared with 
228 µg/L/hour in the RIPC group (extrapolated from 
the similarly mixed cohort of hypoxic and non- hypoxic 
children in Toronto21), with a variability of 220 µg/L/
hour.24 A sample size of at least 52 children per treat-
ment group is needed to have a power of 80% and a 
significance level of 0.05 (two- sided). We therefore will 
recruit at least 104 children (up to 120 children to allow 
for dropouts) randomised in a 1:1 ratio between RIPC 
and control.
Expected recruitment rate
The paediatric cardiac surgery units in Birmingham and 
Leeds are ideally placed to conduct clinical trials. Over 
the preceding 3 years, 99–135 children per annum have 
undergone surgical repair of either tetralogy of Fallot 
(mean 50) or VSD (mean 69) across the two sites.1 The 
only previous interventional trial in cardiac surgery at 
Birmingham Children’s Hospital recruited 22 (79%) 
of the 28 patients approached.45 None of the other UK 
paediatric cardiac surgery RCTs have reported recruit-
ment rates36 but our predictions are comparable to 
those obtained from similar trials in North America 
which ranged from 62% to 84%.27 36 46 We will maintain 
a screening log to document exclusions and reasons 
given by parents who decline to participate; this will be 
available to the Trial Management Committee who will 
monitor recruitment targets and advise on any changes 
to the protocol.
Statistical analysis
Analysis of the main outcome measures will be performed 
according to the intention- to- treat principle and any 
non- adherence to the allocated group documented. The 
primary analysis will assess whether RIPC reduces AUC 
for troponin release in the first 24 hours compared with 
control. The primary outcome measure will be calcu-
lated using the trapezoidal method and presented as an 
adjusted mean difference between groups along with 
the 95% CI estimated using a linear regression model 
(adjusting for the minimisation variables and baseline 
troponin). For the secondary outcomes, continuous data 
items (eg, peak troponin) will also be analysed using a 
linear regression model. Continuous outcomes measured 
across more than three time points (eg, arterial lactate 
and central venous oxygen saturations) will be analysed 
using mixed effect repeated measures models. Time- to- 
event data outcomes will be analysed using a Cox regres-
sion model. Test of interactions will be employed to assess 
whether there is evidence that the treatment effect differs 
between cyanotic and acyanotic patients. P values will be 
reported from two- sided tests at the 5% significance level. 
A detailed statistical analysis plan is under development 
and will be approved prior to database lock. The chief 
investigator and trial statisticians will have access to the 
final trial dataset.
Monitoring
Assessment and management of risk
No adverse events directly attributed to the application of 
a tourniquet cuff during RIPC were identified in a meta- 
analysis of 1762 adults and children undergoing cardiac 
surgery in 25 trials29 nor in any of the notable trials 
published since.19 20 27 28 Risk to participants therefore is 
deemed to be minimal and the trial is categorised as type 
A: no higher than the risk of standard medical care. In 
the event of concern, parents will be signposted to their 
cardiac specialist nurse, their general practitioner or the 
hospital Patient Advice Liaison Service, as appropriate.
Trial Management Committee
The trial will be overseen by a committee meeting approx-
imately every 4 months during the trial. It will comprise 
clinicians, trialists and scientists involved in the set- up 
and running of the trial including representation from 
both trial sites. During recruitment, the protocol may be 
reviewed considering achievement of recruitment targets, 
evidence from new publications and feedback from 
parents approached for the trial; ethical approval for 
amendments to the protocol will be sought, as required.
Data Monitoring Committee
An independent Data Monitoring Committee will meet 
approximately every 8 months during recruitment to 
review efficacy and safety data, according to a predefined 
charter (online supplemental appendix E). Members are 
an academic consultant cardiac surgeon as chair, a consul-
tant in paediatric cardiac intensive care and a statistician. 
Analysis of hs- troponin- T for the primary outcome will 
be performed in batches prior to each meeting and all 
unblinded safety and efficacy data made available to the 
committee.
Safety reporting
Adverse events will be recorded and reported in accor-
dance with the sponsor’s Code of Practice for Research. 
Participants in the study are undergoing open heart 
surgery and therefore adverse events are anticipated. 
The following serious adverse events will be reviewed by 
the chief investigator and reported to the sponsor within 
48 hours of identification: death; requirement for extra-
corporeal life support; evidence of a major neurological 
event; and need for further surgery in the early postoper-
ative period.
Data collection and management
All data will be entered onto the BRICC trial database, 
a password- protected electronic database held on secure 
University of Birmingham servers for trial data with access 
limited to BCTU members of staff working on the trial. 
All paper case report forms will be stored securely in the 
research offices at Birmingham Women’s and Children’s 
National Health Service (NHS) Foundation Trust and 
Leeds Teaching Hospitals NHS Trust. Data will be semi- 
anonymised by removing non- essential potentially identi-
fiable patient information; blood and tissue samples will 
by copyright.
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be labelled with the unique trial ID number, date and 
time of collection. Adherence to trial processes will be 
audited by the independent Clinical Research Compli-
ance team at the University of Birmingham.
Substudies
Metabolic phenotyping
No study in children has previously examined the impact 
of RIPC on myocardial metabolism or its interaction 
with chronic hypoxaemia. Therefore, building on meta-
bolic phenotyping in animal models of IR injury,47 we 
will analyse intraoperative biopsies to identify changes in 
myocardial metabolic pathways that occur during isch-
aemia. In brief, tissue extracts will be analysed using ultra 
high- performance liquid chromatography (UHPLC)–
mass spectrometry in two independent discovery and 
validation phases. Two complementary assays will be 
applied, (1) hydrophilic interaction liquid chromatog-
raphy (HILIC) assay to study water- soluble metabolites, 
including those present in glycolysis and the tricarbox-
ylic acid cycle, and (2) C18 reversed- phase assay to deter-
mine changes in lipids during ischaemia.48 The eluents 
from UHPLC columns will be introduced directly into 
an electrospray Q Exactive Mass Spectrometer (Thermo 
Scientific, UK) and data acquired in the m/z range 
70–1000. The impact of RIPC on metabolism and how 
any changes may be attenuated by preoperative cyanosis 
will be assessed through robust statistical analysis using 
correction for multiple testing and pathway enrichment 
analysis.
Qualitative
We will explore parents’ perspectives on decision- making 
about their child’s participation in a clinical trial as part 
of their elective cardiac surgery. Parents of children 
approached to participate in the trial, both consenters 
and decliners, will be contacted following surgery and 
asked to participate in semistructured interviews which, 
with written informed consent, will be digitally audio- 
recorded, intelligently transcribed and thematically anal-
ysed. The findings will enhance our understanding of the 
factors that influence parents’ decision- making and be 
used to inform the design and conduct of future trials. 
The BRICC trial is a suitable vehicle for this substudy 
as the intervention presents minimal risk, the surgery is 
performed electively and the operations included have a 
low predicted mortality (STAT categories 1–2).49
Patient and public involvement
Patient and public involvement (PPI) has been a central 
component in the development, conduct and planned 
reporting of this trial since its inception. Parents of chil-
dren who had previously undergone cardiac surgery at 
Birmingham Children’s Hospital were contacted through 
Young at Heart, the local children’s heart charity. Four 
parents reviewed the draft parent information sheet and 
consent form for the trial, making suggestions to improve 
clarity and readability for a lay audience, which were 
incorporated into the final versions. The parent informa-
tion sheets, consent forms and protocol for the qualitative 
substudy were also reviewed by the Young Person’s Steering 
Group in the West Midlands. The outcomes of the trial 
will be communicated by individual parent feedback and a 
charity newsletter, both of which will be produced in collab-
oration with the charity and parents. Early user involve-
ment was funded by a bursary from the National Institute 
for Health Research (NIHR) Research Design Service West 
Midlands and all PPI was costed using the INVOLVE Calcu-
lator according to the NIHR’s Budgeting for Involvement.50
ETHICS AND DISSEMINATION
This clinical trial was approved by the West Midlands- 
Solihull NHS Research Ethics Committee (16/WM/0309) 
on 5 August 2016 and the NHS Health Research Authority 
(200876) on 19 August 2016. It is sponsored by the 
University of Birmingham (RG_14-025, email:  research-
governance@ contacts. bham. ac. uk, telephone:+44 (0) 
121 415 8011), registered on the NIHR Clinical Research 
Network portfolio (32330), and approved by the NHS 
Research and Development departments at Birmingham 
Children’s Hospital (1845) and Leeds Children’s Hospital 
(PA17/67348). Regulatory approval from the Medicines 
and Healthcare products Regulatory Agency was not 
required as this trial is not a clinical trial of an investi-
gational medicinal product (CTIMP). The first patient 
was randomised on 24 October 2016 and recruitment is 
currently ongoing.
Changes to the protocol since original ethical approval
Since the original ethical approval, four substantial 
amendments to the protocol have been sought and 
approved with the following significant changes:
 ► Add ‘with/without concomitant pulmonary artery 
repair/augmentation’ to the inclusion criteria, to 
allow inclusion of those with pulmonary artery disease 
within the spectrum of tetralogy of Fallot and those 
with VSD who had previous pulmonary artery banding 
(December 2016).
 ► Add Leeds Children’s Hospital as the second site and 
extend the duration of recruitment (February 2018).
 ► Remove ‘known major chromosomal defect’ as an 
exclusion criterion; although originally included as 
per previous paediatric trials,21 27 following discussion 
with Professor Andrew Redington (Cincinnati, Ohio, 
USA), principal investigator of these trials, it became 
clear that there was no biological reason relating to 
RIPC to exclude these patients (February 2018).
 ► Add Russells Hall Hospital, Dudley as a second core 
laboratory to maintain internal validity, as Sandwell 
General Hospital, Birmingham changed their 
troponin analysis platform during the trial (November 
2019).
Dissemination plan
The findings of the clinical trial and substudies will be 
submitted for presentation at national and international 
by copyright.
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meetings and manuscripts prepared for submission 
to leading journals. The authorship of the final trial 
report will include all members of the trial management 
committee and named collaborators.
Parents of children participating in the trial will be 
informed of the results in writing once data analysis is 
complete. The local charity Young at Heart will also report 
the outcomes in their newsletter to reach a wider audi-
ence of those affected by congenital heart disease. PPI 
collaborators will be invited to participate in producing 
both the parent feedback and charity newsletter.
The first author is chief investigator of the trial and 
takes responsibility for the integrity of this protocol 
report, which adheres to the Standard Protocol Items: 
Recommendations for Interventional Trials recommen-
dations.51 All authors have read and agree to the manu-
script as written.
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